“I’ve never launched a drug quite like this,” Sandoz’s CEO Richard Saynor has admitted frankly, as the firm spoke about its plans to launch GLP-1 assets in the future, starting with semaglutide in markets including Canada and Brazil as early as 2026.
“We currently see eight GLP-1s assets in the market. We’re covering six of those already, and we’re going to look to add as the market is evolving,” Sandoz has revealed, as it delved deeper into what it estimates is a near $60bn loss of exclusivity opportunity in the next decade.
Speaking during the firm’s recent Sandoz Strategic Review 2024 event in Zurich, Switzerland, Sandoz’s management underlined plans in the midterm...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
